Cardiovascular system

SentreHEART Announces Initial Clinical Use of the LARIAT® with EpiRAIL™ Procedure for Left Atrial Appendage Exclusion

Retrieved on: 
Tuesday, July 30, 2019

The LARIAT with EpiRAIL is an epicardial-only, percutaneous approach to complete and permanent closure of the left atrial appendage (LAA) in patients with atrial fibrillation and increased risk of stroke.

Key Points: 
  • The LARIAT with EpiRAIL is an epicardial-only, percutaneous approach to complete and permanent closure of the left atrial appendage (LAA) in patients with atrial fibrillation and increased risk of stroke.
  • The LARIAT with EpiRAIL eliminates the requirement of a transseptal catheterization in order to enter the left atrium of the heart.
  • Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage.
  • Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients with Atrial Fibrillation.

Rising Prevalence of Cardiac Diseases Anticipated to Create Massive Demand for Cardiac Holter Monitor - TMR

Retrieved on: 
Thursday, July 25, 2019

The cardiac holter monitor is used at a large scale for diagnosis and analysis of atrial fibrillation, cardiac arrhythmia, and bradycardia.

Key Points: 
  • The cardiac holter monitor is used at a large scale for diagnosis and analysis of atrial fibrillation, cardiac arrhythmia, and bradycardia.
  • According to Transparency Market Research (TMR), the global cardiac holter monitor market is prognosticated to project a steady CAGR of 6.6% within the forecast period from 2016 to 2024.
  • The rising cases of coronary illness inferable from tobacco use, physical inactivity, harmful consumption of alcohol, and poor eating regimen boosts the cardiac holter monitor market.
  • Geographically, North America held major share in 2015, of global cardiac holter monitor market.

Rising Prevalence of Cardiac Diseases Anticipated to Create Massive Demand for Cardiac Holter Monitor - TMR

Retrieved on: 
Thursday, July 25, 2019

The cardiac holter monitor is used at a large scale for diagnosis and analysis of atrial fibrillation, cardiac arrhythmia, and bradycardia.

Key Points: 
  • The cardiac holter monitor is used at a large scale for diagnosis and analysis of atrial fibrillation, cardiac arrhythmia, and bradycardia.
  • According to Transparency Market Research (TMR), the global cardiac holter monitor market is prognosticated to project a steady CAGR of 6.6% within the forecast period from 2016 to 2024.
  • The rising cases of coronary illness inferable from tobacco use, physical inactivity, harmful consumption of alcohol, and poor eating regimen boosts the cardiac holter monitor market.
  • Geographically, North America held major share in 2015, of global cardiac holter monitor market.

Critical Limb Ischemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Retrieved on: 
Tuesday, July 23, 2019

Global Critical Limb Ischemia Treatment Market: Overview

Key Points: 
  • Global Critical Limb Ischemia Treatment Market: Overview
    This report analyzes the current and future scenario of the global critical limb ischemia treatment market.
  • The global critical limb ischemia treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.It also provides information and data analysis of the global market with respect to the segments based on treatment, and region.
  • Global Critical Limb Ischemia Treatment Market: Key Segments
    Based on treatment, the global critical limb ischemia treatment market has been segmented into devices and medications.The segments have been analyzed based on available devices and drug products used in the treatment of critical limb ischemia, cost-effectiveness, and preference for industries.
  • The global critical limb ischemia treatment market has been segmented as below:
    Global Critical Limb Ischemia Treatment Market, by Treatment

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

Retrieved on: 
Tuesday, July 23, 2019

TIANJIN, China, July 23, 2019 /PRNewswire/ -- In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial.

Key Points: 
  • TIANJIN, China, July 23, 2019 /PRNewswire/ -- In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial.
  • The PIONEER III trial is designed to assess the safety and effectiveness of the BuMA Supreme DES and support U.S. and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
  • "This earlier restoration can lead to safer long-term results by possibly reducing late stent thrombosis and neo-atherosclerosis."
  • More information on the PIONEER III study is available at www.clinicaltrials.gov , identifier: NCT03168776.

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

Retrieved on: 
Tuesday, July 23, 2019

TIANJIN, China, July 23, 2019 /PRNewswire/ -- In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial.

Key Points: 
  • TIANJIN, China, July 23, 2019 /PRNewswire/ -- In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial.
  • The PIONEER III trial is designed to assess the safety and effectiveness of the BuMA Supreme DES and support U.S. and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
  • "This earlier restoration can lead to safer long-term results by possibly reducing late stent thrombosis and neo-atherosclerosis."
  • More information on the PIONEER III study is available at www.clinicaltrials.gov , identifier: NCT03168776.

New study finds both components of blood pressure predict heart attack, stroke risk

Retrieved on: 
Wednesday, July 17, 2019

Systolic pressure the upper number in a blood pressure reading measures how hard the heart pumps blood into arteries.

Key Points: 
  • Systolic pressure the upper number in a blood pressure reading measures how hard the heart pumps blood into arteries.
  • Diastolic pressure the bottom number indicates the pressure on the arteries when the heart rests between beats.
  • Decades of research have shown that high systolic blood pressure is more likely to result in adverse outcomes.
  • The results are also in keeping with findings from the National Institutes of Health's Systolic Blood Pressure Intervention Trial, known as SPRINT .

LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula

Retrieved on: 
Tuesday, July 16, 2019

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery.

Key Points: 
  • LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery.
  • LivaNova Bi-Flow received CE Mark earlier this year and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery procedures requiring femoral artery cannulation.
  • The innovative, patented and award-winning design of the bidirectional cannula incorporates a unique shoulder and downstream perfusion channel that enables continuous and reliable blood flow down the femoral artery.
  • Limb ischemia is an often-underestimated potential side effect of femoral artery cannulation, and it can have dramatic consequences, said Alistair Simpson, LivaNova General Manager of Cardiac Surgery.

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Retrieved on: 
Monday, July 15, 2019

Gadavist is now the first and only contrast agent FDA approved for use in cardiac MR an important diagnostic tool for patients with CAD.

Key Points: 
  • Gadavist is now the first and only contrast agent FDA approved for use in cardiac MR an important diagnostic tool for patients with CAD.
  • "A Gadavist-enhanced cardiac MR is a key diagnostic tool, providing additional important clinical information, which can help physicians manage their patients with known or suspected CAD."
  • Eventually, the decreased blood flow may cause chest pain (angina), shortness of breath, or other coronary artery disease signs and symptoms.
  • To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD).

Publication of UNCOVER AF Study in Circulation Demonstrates Impact of Charge Density Mapping During AF Ablation

Retrieved on: 
Thursday, July 11, 2019

CARLSBAD, Calif., July 11, 2019 /PRNewswire/ -- Acutus Medical today announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology .

Key Points: 
  • CARLSBAD, Calif., July 11, 2019 /PRNewswire/ -- Acutus Medical today announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology .
  • The study demonstrated 73 percent single-procedure freedom from atrial fibrillation (AF) at 12 months with the use of Acutus' AcQMap advanced cardiac imaging and mapping system.
  • Strokes caused by AF are also more severe than strokes with other underlying causes, indicating the importance of effective treatment.
  • "The publication of UNCOVER AF showcases the impact that better tools can have on patients and physicians," said Vince Burgess, CEO of Acutus Medical.